)
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Move comes amid concerns over safety lapses involving contaminated solvents
The proposed amendment would bring antibiotics, antivirals and antifungals under the Central Licensing Authority, strengthening requirements for safety, efficacy and bioequivalence data
Drug price regulator extends knee implant price caps for two months as manufacturers seek revisions, while domestic medtech firms call for stability and a review of trade margins
Government-funded health schemes and private insurance accounted for 21.2 per cent of India's total health expenditure in FY24, with both categories crossing 10 per cent for the first time
An expert committee has recommended Phase I clinical trials for the vaccine developed by Indian Immunologicals and Australia's Griffith University, following a review of non-clinical studies
Revised scheme brings component makers and MSMEs into the incentive framework, with higher incentives for critical components and high-end devices to deepen localisation
Drug pricing regulator NPPA asks state drug controllers to submit action-taken reports by November 16 as a 30 per cent trade margin cap on 137 cancer drugs takes effect
Despite progress, India still had the highest TB burden, accounting for almost a quarter of global cases in 2025
The revised scheme removes the minimum sales threshold, lowers investment requirements and offers higher incentives for critical components and advanced medical devices
Delhi's AQI touched 372 on Monday after Diwali celebrations, triggering health concerns, questions over pollution monitoring and a political row over stubble burning in Punjab
Fortis Healthcare's Q2FY27 net profit declined to ₹320 crore as expenses rose, while revenue grew 17 per cent to ₹2,735 crore, driven by hospitals and diagnostics
The Health Ministry has proposed suspending manufacturing licences immediately after drugs fail critical quality tests, aiming to prevent unsafe medicines from remaining in circulation.
The Union Health Ministry has proposed tightening microbial contamination limits in Grade A clean areas to align India's pharmaceutical manufacturing standards with WHO guidelines
Manipal Health Enterprises will develop and operate a multi-specialty hospital on 3.5 acres in Gurugram under a 30-year lease, with the estimated investment pegged at ₹750 crore
Dr Lal PathLabs reported a 19.6 per cent rise in Q2FY27 revenue to ₹874 crore as sample volumes grew 13.6 per cent and patient coverage increased 9 per cent
The Health Ministry proposes adding seven inland container depots, an SEZ and Jewar airport to the approved list to ease imports of drugs, medical devices and cosmetics
The proposed amendments seek to strengthen accountability in drug manufacturing by requiring qualified personnel for batch release and maintaining prescribed records
Pharma executives seek clarity on export applicability of CDSCO's batch-wise solvent clearance rules, warning that approval delays could disrupt supplies, particularly in rural markets
Drug regulator CDSCO has mandated digital clearance for every batch of high-risk pharmaceutical solvents, prompting industry concerns over delays and potential supply disruptions
The drugmaker plans to deploy ₹500 crore for another acquisition within 12 months as it targets 25 per cent annual growth in its API business over the next five years